EVASC-NEUROVASCULAR
23.2.2021 07:31:12 CET | Business Wire | Press release
Evasc Neurovascular is proud to announce its successful application to France’s Ministry of Health (Haute Autorité de la Santé, HAS) Forfait Innovation (FI) program for the eCLIPs™ device, published in its official journal December 23, 2020 - https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000042722732 .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005015/en/
The Forfait Innovation program grants clinical trial funding to evaluate CE marked devices that are deemed to be truly innovative (not simply incremental developments) and offer significant clinical benefit, filling an unmet medical need. The eCLIPs device is the first neuro device that has gained FI approval and funding. The funded amount of €2.76 million covers hospital costs of a 119-patient trial against optimal performance criteria (OPC).
Dr. Donald Ricci, CEO of Evasc Neurovascular, comments, “We are pleased to have confirmation by an influential and independent third party, the French Ministry of Health, that eCLIPs represents an innovation in the treatment of intracranial bifurcation aneurysms, a consistent message in our presentations, publications and discussions with neuro-interventionalists over the past few years.”
About the eCLIPs Aneurysm Treatment System
eCLIPs is a non-tubular endovascular device currently targeted for use in challenging wide-neck bifurcations, using technology designed to treat 95% of cerebral aneurysm cases. The unique eCLIPs design provides not only coil retention, but also flow diversion at the neck. eCLIPs avoids dangerous entry into the dynamic, fragile environment of the aneurysm sac while leaving side branches unencumbered and providing a platform for endothelial growth across the bifurcation neck.
About Evasc Neurovascular
Evasc Neurovascular is a privately-held medical device company focused on the development of disruptive endovascular treatments for cerebral aneurysms. Evasc Neurovascluar is headquartered in Vancouver, Canada.
Visit Evasc Neurovascular at www.evasc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005015/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Comrade Trustee Services goes live with Smartstream’s Air, the AI reconciliation and data automation solution11.6.2026 09:55:00 CEST | Press release
Key Facts Comrade Trustee Services is live on Smartstream’s Air for automated reconciliations with fully integrated workflows. The implementation replaces highly manual, spreadsheet-driven processes and complex file handling with a single-click, straight-through AI-driven workflow. This will improve accuracy, control and operational efficiency. Processing time has been reduced from up to eight hours to under five minutes, with additional scalability for complex file types, formats and reconciliation logic. Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces that Comrade Trustee Services Limited (CTSL), trustee for the Defence Force Retirement Benefit Fund in Papua New Guinea, has gone live with Smartstream’s Air, the AI reconciliation and data automation solution – cutting processing times from eight hours to under five minutes. The go-live delivers a fully automated, straight-through reconciliation workflow, enabl
Wolters Kluwer enhances its Libra legal AI workspace in Italy by adding content specializations for One and integrating with Kleos11.6.2026 09:00:00 CEST | Press release
Libra by Wolters Kluwer integrates AI with authoritative, expert-generated content and operational workflows, supporting legal professionals across the entire workflow Wolters Kluwer Legal & Regulatory announced today new content and feature integrations in its legal AI workspace Libra by Wolters Kluwer for the Italian market. Customers will have access to additional expert-generated content in compliance, criminal law and tax law, and profit from the integration with Kleos, the cloud-based practice management solution for law firms. Designed to support the daily work of legal professionals, Libra by Wolters Kluwer combines advanced AI functionalities with trusted sources and authoritative, author-generated legal content. Within a single environment, it enables research, analysis and drafting activities based on reliable sources, while maintaining full control over results and quality. By integrating additional expert content from One, Wolters Kluwer’s leading legal research platform,
Pleo Announces New Agentic Capabilities, Changing the Face of Financial Management and Decision-Making11.6.2026 09:00:00 CEST | Press release
Pleo’s new agentic capabilities to let finance teams focus on strategic command, not admin These new agentic capabilities offer a clear path forward for finance leaders: especially when 63% say AI skills, training and confidence are severely lagging. Pleo, Europe's first and most trusted strategic finance platform, today announces a suite of AI agents that handle routine spend management autonomously, so finance leaders can focus on decisions rather than administrative tasks. Finance teams are under growing pressure: 45% of European companies say their current processes slow them down, and leaders describe approval workflows as so cumbersome they struggle to operate at the required speed. Meanwhile, 73% believe the future of finance teams and professionals depends on the comprehensive understanding and use of AI, yet 63% say AI skills, training and confidence are severely lagging. Pleo's agentic AI addresses this gap. Starting with beta testing in July, Pleo is moving toward a model wh
BearingPoint Danmark leverer 85% omsætningsvækst i 2025 og offentliggør års- og bæredygtighedsrapport11.6.2026 09:00:00 CEST | Pressemeddelelse
Stærk kundeefterspørgsel, et banebrydende AI projekt med Danske Bank og en betydelig medarbejdervækst skaber fremdrift på det danske marked og omsætter Strategy 2030 til konkrete resultater i Danmark. BearingPoint Danmark opnåede en omsætningsvækst på 85% i 2025, drevet af stærk efterspørgsel efter AI og rådgivning til den finansielle sektor, i forbindelse med offentliggørelsen af virksomhedens Årsrapport 2025, ”Future in focus” samt Bæredygtighedsrapport 2025, som markerer overgangen fra strategi til konkret eksekvering. Rapporterne viser, hvordan virksomheden skalerer anvendelsen af AI på tværs af organisationen, styrker sin globale leverancemodel og integrerer bæredygtighed i både strategi og kundeleverancer. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260611802927/da/ BearingPoint Danmark opnåede en omsætningsvækst på 85% i 2025, drevet af stærk efterspørgsel efter AI og rådgivning til den finansielle sektor, i forb
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions11.6.2026 08:01:00 CEST | Press release
- Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consistent with the durable benefits established in patients 12 years and older -- Data simultaneously published in the New England Journal of Medicine -- Regulatory review underway in the United States to expand the use of CASGEVY, and Vertex has recently completed submissions in the Kingdom of Saudi Arabia and United Kingdom - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with the transformative profile established in adult and adolescent p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom